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Abstract 106 
 107 
Epigenetic modifications, including DNA methylation, represent a potential mechanism for 108 
environmental impacts on human disease. Maternal smoking in pregnancy remains an 109 
important public health problem that impacts child health in myriad ways with potential lifelong 110 
consequences. Mechanisms are largely unknown but epigenetics likely plays a role. We formed 111 
the Pregnancy And Childhood Epigenetics (PACE) consortium and meta-analyzed, across 13 112 
cohorts (N=6,685), the association between maternal smoking in pregnancy and newborn blood 113 
DNA methylation at over 450,000 CpG sites using the Illumina 450K Beadchip. Over 6,000 114 
CpGs were differentially methylated in relation to maternal smoking at genome-wide statistical 115 
significance (False Discovery Rate 5%), including 2,965 CpGs corresponding to 2,017 genes 116 
not previously related to smoking and methylation in either newborns or adults. Some genes are 117 
relevant to diseases that can be caused by maternal smoking (e.g. orofacial clefts and asthma) 118 
or adult smoking (e.g. certain cancers). A number of differentially methylated CpGs were 119 
associated with gene expression. We observed enrichment in pathways and networks critical in 120 
development. In older children (5 cohorts, N=3,187) 100% of CpGs gave at least nominal levels 121 
of significance, far more than expected by chance (p value < 2.2 x 10-16). Results were robust to 122 
different normalization methods used across studies and cell type adjustment. In this large scale 123 
meta-analyses of methylation data, we identified numerous loci involved in response to maternal 124 
smoking in pregnancy with persistence into later childhood and provide insights into 125 
mechanisms underlying effects of this important exposure.  126 
 127 
  128 
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Introduction 129 
Despite years of advisories regarding health risks to the developing fetus from maternal 130 
smoking, many pregnant women still smoke: 12.3% in the U.S.{Tong, 2013 #28} Maternal 131 
smoking during pregnancy is regarded as a cause of low birth weight, reduced pulmonary 132 
function (PLF [MIM: 608852]), orofacial clefts (OFC1 [MIM: 119530]), and sudden infant death 133 
syndrome (SIDS [MIM: 272120]) in exposed newborns.{US Department of Health and Human 134 
Services, 2014 #27} Other adverse birth outcomes{Moritsugu, 2007 #95} have been associated 135 
with maternal smoking in pregnancy along with common health problems in children including 136 
asthma (ASRT [MIM: 600807]), otitis media (OMS [MIM: 166760]), and neurobehavioral 137 
disorders.{US Department of Health and Human Services, 2014 #27}  138 
The mechanisms for the adverse health effects of maternal smoking during pregnancy 139 
on offspring remain poorly understood.{US Department of Health and Human Services, 2014 #27} 140 
Recently, studies have examined the potential role of epigenetic modifications such as DNA 141 
methylation at specific CpG sites (CpGs). These include studies examining genome-wide DNA 142 
methylation in newborns in relation to maternal smoking in pregnancy using the Illumina Infinium 143 
HumanMethylation27 (27K) BeadChip{Breton, 2014 #102;Flom, 2011 #4;Suter, 2011 #8} or the 144 
newer platform with wider coverage, HumanMethylation450 (450K) BeadChip.{Joubert, 2012 145 
#5;Markunas, 2014 #7;Richmond, 2015 #159;Kupers, 2015 #99} A number of differentially 146 
methylated loci have been identified in offspring in relation to maternal smoking in pregnancy in 147 
individual studies (references in Supplemental Note). One study examined the top CpGs with 148 
respect to timing of exposure and found that the signals reflect sustained, rather than short-149 
term, exposure to maternal smoking during pregnancy{Joubert, 2014 #10} but this has not been 150 
evaluated genome-wide. A few studies suggest that some of these methylation signals persist 151 
into later childhood and adolescence but data are limited.{Lee, 2015 #91;Richmond, 2015 #159} 152 
Combining genome-wide data across studies using meta-analysis to generate large sample 153 
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sizes for the discovery of loci that would not have been identified from individual studies has 154 
been very successful in genetics, but this approach has rarely been used with methylation data.  155 
To address the impact of maternal smoking during pregnancy on newborns with much 156 
greater power, we recruited 13 birth cohort studies with data on maternal smoking during 157 
pregnancy and DNA methylation in offspring from the 450K Beadchip into the Pregnancy and 158 
Child Epigenetics consortium (PACE). We meta-analyzed harmonized cohort-specific 159 
associations between maternal smoking during pregnancy and DNA methylation in the 160 
offspring. We examined both sustained maternal smoking and any smoking during pregnancy. 161 
We also examined persistence of DNA methylation patterns related to maternal smoking in 162 
newborns among older children, including adjustment for postnatal secondhand tobacco smoke 163 
exposure. For functional follow-up of findings we evaluated the associations between 164 
methylation status in the newly identified CpG sites and expression levels of nearby genes and 165 
performed pathway and functional network analyses. This study represents a large and 166 
comprehensive approach to evaluating the impact of maternal smoking during pregnancy on 167 
DNA methylation in offspring. 168 
 169 
Material and Methods 170 
 171 
Participating cohorts 172 
 A total of 13 PACE cohorts participated in the meta-analysis of maternal smoking during 173 
pregnancy and 450K DNA methylation in newborns. These studies, listed in alphabetical order, 174 
are the Avon Longitudinal Study of Parents and Children (ALSPAC), the Center for Health 175 
Assessment of Mothers and Children of Salinas (CHAMACOS), the Children’s Health Study 176 
(CHS), the GECKO Drenthe cohort, the Generation R Study, Isle of Wight (IOW), Mechanisms 177 
of the Development of Allergy (MeDALL), three independent datasets from the Norwegian 178 
Mother and Child Cohort Study (MoBa1, MoBa2, and MoBa3), the Norway Facial Clefts Study 179 
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(NFCS), the Newborn Epigenetics Study (NEST), and Project Viva (VIVA). MeDALL represents 180 
a pooled analysis of four cohorts with coordinated methylation measurements: Infancia y Medio 181 
Ambiente (INMA), Etudes des Déterminants pré et postnatals précoces du développement et de 182 
la santé de l’ENfant (EDEN), Children’s Allergy Environment Stockholm Epidemiology study 183 
(BAMSE), and Prevention and Incidence of Asthma and Mite Allergy (PIAMA). Two of the 184 
MeDALL cohorts contributed to the newborn meta-analysis (INMA and EDEN). There were five 185 
studies with data on older children: ALSPAC, Genes-environments and Admixture in Latino 186 
Americans (GALA II), the Study to Explore Early Development (SEED), MeDALL (INMA, EDEN, 187 
BAMSE, and PIAMA), and an independent methylation dataset from BAMSE subjects. The 188 
study methods for each cohort are described in detail in the supplemental material (see 189 
Supplemental Note).  190 
 191 
Harmonization of maternal smoking variables 192 
Cohorts assessed maternal smoking during pregnancy using questionnaires completed 193 
by the mothers. The MoBa study (MoBa 1 and MoBa 2) also used cotinine measurements from 194 
maternal blood samples taken during pregnancy as part of the definition of maternal smoking 195 
during pregnancy. More details on the cohort-specific smoking variables are in the 196 
Supplemental Note. In a previous publication from the MoBa1 study, significant associations 197 
between maternal smoking during pregnancy and DNA methylation in newborns were driven not 198 
by transient smoking that ended early in pregnancy but rather by sustained smoking during 199 
pregnancy.{Joubert, 2014 #10} Thus, each cohort ran separate models to evaluate both 200 
sustained smoking and any smoking during pregnancy. The sustained smoking during 201 
pregnancy (yes/no) variable was designed to capture women who smoked at least one cigarette 202 
per day through most of pregnancy. To cleanly contrast the effect of sustained smoking through 203 
pregnancy to never smoking during pregnancy, we excluded women who reported quitting 204 
smoking during pregnancy from the sustained smoking models. The any maternal smoking 205 
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during pregnancy (yes/no) variable was designed to capture any amount of smoking during 206 
pregnancy, at any time, even if a woman reported quitting. Because we did not exclude women 207 
who quit smoking during pregnancy from the any smoking during pregnancy models, the total 208 
sample sizes are slightly larger compared to the sustained smoking during pregnancy models. 209 
Genome-wide analyses use large sample statistics. We limited meta-analyses to cohorts with at 210 
least 15 subjects in both the exposed and unexposed groups. This excluded four cohorts 211 
(CHAMACOS, CHS, IOW, and VIVA) from the sustained smoking models. However these 212 
cohorts did participate in the any smoking during pregnancy meta-analysis. 213 
 214 
Methylation measurements and quality control 215 
Each cohort independently conducted laboratory measurements and quality control. The 216 
samples for each cohort underwent bisulfite conversion using the EZ-96 DNA Methylation kit 217 
(Zymo Research Corporation, Irvine, USA). Samples were processed with the Illumina Infinium 218 
HumanMethylation450 (450K) BeadChip (Illumina Inc., San Diego, USA) at Illumina or in cohort-219 
specific laboratories.  220 
Quality control of samples was performed by each cohort and included the exclusion of 221 
failed samples based on Illumina’s detection p value, low sample DNA concentration, sample 222 
call rate, CpG specific percentage of missing values, bisulfite conversion efficiency, gender 223 
verification with multidimensional scaling plots, and other quality control metrics specific to 224 
cohorts. Cohorts could also use validated, published statistical methods for normalizing their 225 
methylation data on the untransformed methylation beta values (ranging from 0 to 1). Some 226 
cohorts also made independent probe exclusions. More details are provided in the 227 
Supplemental Note. For the meta-analysis, additional probe exclusions were made across all 228 
cohorts. Specifically, we excluded control probes (N=65), probes that mapped to the X 229 
(N=11,232) or Y (N=416) chromosomes, probes with an underlying SNP mapping to the last five 230 
nucleotides of the probe sequence (N=9,168) as previously described{Joubert, 2012 #5} and 231 
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CpGs with an implausible (zero) value for the standard error (N=67). This left a total of 464,628 232 
CpGs included in the meta-analysis.  233 
 234 
Cohort-specific statistical analyses 235 
Each cohort ran independent statistical analyses according to a common pre-specified 236 
analysis plan. Robust linear regression was used in R{R Core Team, 2013 #11} to evaluate the 237 
association between maternal smoking during pregnancy and cord blood DNA methylation for 238 
each probe while accounting for potential heteroskedasticity and/or influential outliers. Each 239 
cohort ran the following covariate-adjusted statistical models: 1) the primary model, using 240 
sustained maternal smoking during pregnancy as the exposure and the normalized betas as the 241 
outcome, 2) sustained maternal smoking during pregnancy as the exposure and raw betas (not 242 
normalized) as the outcome, 3) any maternal smoking during pregnancy as the exposure and 243 
normalized betas as the outcome, 4) any maternal smoking during pregnancy as the exposure 244 
and raw betas as the outcome, and 5) sustained maternal smoking during pregnancy as the 245 
exposure and normalized betas as the outcome, with additional adjustment for cell type 246 
proportion. All models were adjusted for maternal age, maternal education (or a surrogate 247 
socioeconomic metric), parity, and technical covariates such as batch or plate. Some cohorts 248 
used ComBat{Leek, 2012 #52} to account for batch effects, and therefore did not include 249 
batch/plate as covariates in the models with normalized betas (see Supplemental Note). 250 
Additional correction for study design/sampling factors was done as needed in some cohorts. 251 
Because maternal smoking during pregnancy is not related to the child's sex, it cannot be a 252 
confounder and thus was not included in models. We did not adjust for principal components 253 
(PCs) because not all cohorts had genome wide genotype data and cohorts with genotype data 254 
had it only for a subset of subjects with methylation data. Furthermore, in one large cohort with 255 
PC data, models adjusted for PCs compared to models without PCs showed little variation in 256 
the results (correlation of betas =0.991; correlation of log(P-values)=0.996), despite a reduction 257 
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in sample size. The statistical models for cohorts with DNA methylation measured in older 258 
children were the same, with the additional adjustment for second-hand tobacco smoke 259 
exposure.  260 
All cohorts independently estimated cell type proportion using the reference-based 261 
Houseman method{Houseman, 2012 #13} in the minfi package{Aryee, 2014 #55} using the 262 
Reinius et al. dataset for reference.{Reinius, 2012 #56} Cell type correction was applied by 263 
including the six estimated cell type proportions (CD8T, CD4T, NK cells, B cells, monocytes, 264 
granulocytes) as covariates in cohort-specific statistical models.  265 
 266 
Meta-analysis 267 
We performed inverse variance-weighted fixed-effects meta-analysis with 268 
METAL.{Willer, 2010 #16} Multiple testing was accounted for by controlling the false discovery 269 
rate (FDR) at 5%, implementing the method by Benjamini and Hochberg.{Benjamini, 1995 #17} 270 
This method was applied to all instances of FDR correction described in this paper unless 271 
otherwise specified. CpGs with an FDR-corrected p value less than 0.05 were considered 272 
statistically significant. CpGs that were statistically significant based on the more stringent 273 
Bonferroni correction (uncorrected p value <1.08x10-7 to account for 464,628 tests) were also 274 
noted.  275 
To determine the robustness of our models and findings, we performed an additional 276 
analysis removing the cohorts of non-European ancestry (Supplemental Table S1). We 277 
compared the effect estimates, standard errors, and the distribution of the p values for the 278 
model to the estimates for our primary model to evaluate the consistency of our findings.  279 
 280 
Examination in older children of CpGs associated with smoking in cord blood  281 
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The FDR significant CpGs identified in the primary model from the newborn meta-282 
analyses were followed up using a lookup replication approach in the results from five older 283 
children cohorts, applying FDR correction to account for the number of CpGs tested.  284 
 285 
Literature review to identify genes previously associated with smoking and methylation  286 
We performed a systematic literature review to determine which CpGs represented 287 
findings not previously related to smoking exposure and methylation in the literature. A query of 288 
NCBI's PubMed database was performed using the search terms (("DNA Methylation"[Mesh] 289 
OR methylation) AND ("Smoking"[Mesh] OR smoking)) to be broad enough to capture all past 290 
studies reporting such results. CpGs with previously reported associations with smoking, both 291 
from prenatal exposure or in adults, were considered. This search yielded 789 results when 292 
performed on March 1, 2015. All results were then reviewed by title and abstract to determine 293 
whether they met inclusion criteria. First, results were limited to those performed in healthy 294 
human populations. That is, participants could not exclusively have been drawn from disease 295 
cases, such as cancer patients, and could not have been performed only in cell lines or animal 296 
studies. Case-control analyses that included healthy controls were accepted as meeting this 297 
criterion and no limitation was applied concerning the tissue used for DNA extraction. Second, 298 
studies were required to have performed DNA methylation analysis agnostically on a large scale 299 
as opposed to targeted interrogation of candidate CpG sites. This was operationalized by 300 
including only analyses that examined >1,000 sites simultaneously. The Illumina 450K, 27K, 301 
and GoldenGate arrays all met this criterion. Third, the exposure was restricted to tobacco 302 
cigarette smoking. Related exposures, such as to other forms of tobacco use or smoke 303 
exposure, were not included. Lastly, studies had to have reported their significant results 304 
publicly. Studies that failed to report p values or gene annotations were excluded.  305 
Review of the existing literature on the effect of smoking on DNA methylation identified 25 306 
publications meeting inclusion criteria. Of these, 16 studies reported results for adult smoking 307 
11 
 
exposure,{Besingi, 2014 #111;Breitling, 2011 #112;Dogan, 2014 #92;Elliott, 2014 308 
#114;Flanagan, 2015 #115;Guida, 2015 #116;Philibert, 2012 #118;Philibert, 2013 309 
#117;Shenker, 2013 #58;Siedlinski, 2012 #120;Sun, 2013 #121;Tsaprouni, 2014 #122;Wan, 310 
2012 #124;Wan, 2014 #123;Zaghlool, 2015 #125;Zeilinger, 2013 #59} while nine provided 311 
results of association between maternal smoking during pregnancy on child DNA 312 
methylation.{Breton, 2014 #102;Chhabra, 2014 #103;Harlid, 2014 #93;Ivorra, 2015 #88;Joubert, 313 
2012 #5;Lee, 2015 #91;Maccani, 2013 #108;Markunas, 2014 #7;Richmond, 2015 #159} CpG 314 
level results (p values and gene annotations) for sites showing significant association between 315 
smoking exposure and DNA methylation were extracted and compiled for comparison with the 316 
results from the meta-analysis. Results were considered significant if they met the multiple 317 
testing criteria implemented within the publication. For studies failing to implement any multiple 318 
testing correction, a naive Bonferroni threshold for the number of tests performed in the 319 
individual study was used. Genes previously associated with either adult smoking or maternal 320 
smoking in pregnancy (Supplemental File 3) and were excluded from our list of meta-analysis 321 
results.  322 
 323 
CpG annotation  324 
The official gene name was noted for each CpG using Illumina’s genome coordinate.{, 325 
2014 #19} We enhanced the annotation provided by Illumina based on the RefSeq database 326 
with additional UCSC and Ensembl databases, as well as annotation data in Bioconductor. All of 327 
the annotations use the human Feb. 2009 (GRCh37/hg19) assembly. We also used the 328 
package Snipper to annotate the nearest genes within 10 Mb of each CpG. We include this 329 
expanded Snipper gene annotation in our tables and discussion.  330 
For selected genes, we used CoMet{Martin, 2015 #138} to graphically display additional 331 
information about CpGs including physical location, correlation, statistical significance, and 332 
functional annotation. 333 
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 334 
Enrichment analysis 335 
We evaluated whether the CpGs significantly associated with smoking (based on the 336 
FDR p value < 0.05) were enriched, relative to all CpGs analyzed, for several biologic 337 
annotations provided in the Illumina annotation file. We assessed enrichment using the two-338 
sided doubling mid p value of the hypergeometric test.24 We also evaluated enrichment in a 339 
subset of CpGs mapping to imprinted differentially methylated regions (DMRs) described by 340 
Court et al.{Court, 2014 #31}  341 
 342 
Pathway analyses 343 
We linked the CpGs significantly associated with smoking (based on the FDR p value < 344 
0.05) to genes based only on the 450K BeadChip annotation file.{Triche, 2014 #20} Probes 345 
lacking an annotated Entrez Gene ID were filtered (n=1,971), as were duplicate gene entries 346 
(n=1,473). A total of 2,629 unique gene identifiers were used in gene ontology enrichment 347 
analysis with three different procedures as described below.  348 
This resulted in 2,235 genes that mapped to gene ontologies of biological processes and 349 
we tested for gene enrichment over the background array (16,119 unique annotated Entrez 350 
Gene IDs) using Fisher’s exact tests with a minimum of five genes per node using topGO in 351 
R.{Alexa, 2010 #21} In addition, we used the DAVID bioinformatics resource{Huang da, 2009 352 
#22} to test for enrichment in gene ontology biological processes with a threshold of five, using 353 
the Benjamini-Hochberg procedure to control for false discoveries. Finally, we used QIAGEN’s 354 
Ingenuity Pathway Analysis to identify relevant signaling and functional pathways (IPA, 355 
Redwood City, CA, www.qiagen.com/ingenuity). 356 
 357 
Functional network analysis 358 
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To construct a functional association network, it was desirable to reduce the list of tested 359 
CpGs, so we prioritized the FDR significant CpGs from the primary model in a stepwise manner. 360 
First, we only included those CpGs that were FDR significant in both the primary and cell type 361 
adjusted models (FDR P values <0.05). Next, we sorted these CpGs based on their effect size 362 
(beta coefficient), and selected the top quartile (N=980). The genes mapping to these prioritized 363 
CpGs were then used as input for the construction of a functional interaction network. We used 364 
the GeneMANIA algorithm as well as its functional association data including genetic 365 
interaction, physical interactions, co-expression, shared protein domains, and co-localization 366 
networks.{Warde-Farley, 2010 #85} We selected the “all available networks” option with a 500-367 
gene output (accessed March 11, 2015). Functional enrichment analysis was then performed on 368 
all genes from the constructed interaction network against Gene Ontology (GO) terms to detect 369 
significantly enriched GO terms.{Vaez, 2015 #86} FDR correction was applied to this analysis 370 
based on the q-value using a threshold of q<0.01.  371 
 372 
Methylation transcription analysis 373 
To further explore the associations between methylation and gene expression, we 374 
performed methylation-expression analyses, evaluating the association between methylation 375 
status of CpGs and differences in quantitative levels of gene expression. All identified CpGs that 376 
reached FDR-corrected significance and that we identified as not previously reported in the 377 
literature were tested for association with expression levels of genes within a region of 250 kb 378 
upstream or downstream of the CpG{Zhang, 2014 #160} (total region 500kb), to evaluate 379 
whether the CpG-methylation status influenced transcript levels of genes. We had two data sets 380 
available for this analysis. One dataset included mRNA gene expression (Illumina 381 
HumanHT12v4) and 450K methylation data, both from whole blood samples from 730 adults 382 
over 45 years of age in the Rotterdam Study, a population-based prospective cohort study in 383 
Rotterdam, the Netherlands.{Hofman, 2013 #127} This gene expression dataset is available at 384 
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GEO (Gene Expression Omnibus) public repository under the accession GSE33828. The 385 
second dataset included mRNA gene expression (Affymetrix HTA 2.0) and 450K methylation 386 
data on whole blood samples from 107 children aged 4 years from the INMA study in Spain. 387 
Study population details for the Rotterdam Study and INMA are in the supplementary note. In 388 
the Rotterdam dataset, 2,636 of the 2,965 CpGs examined mapped to a transcript within the 389 
500kb window. We created residuals for mRNA expression after regressing out the Houseman 390 
estimated white blood cell proportions, the erythrocytes and platelets cell counts, fasting state, 391 
RNA quality score, plate number, age, and sex on the mRNA expression levels using a linear 392 
mixed model. We then created residuals for DNA methylation regressing out the Houseman 393 
estimated white blood cell proportions, age, sex, batch effects on the dasen normalized beta-394 
values of the CpG sites using a linear mixed model. We used a linear regression model to 395 
evaluate the association between the residuals of the mRNA expression levels and the 396 
residuals of the dasen normalized beta-values of the CpG sites.  397 
The INMA gene expression data was normalized using Expression Console Software 398 
from Affymetrix and probes were clustered to the transcript level. Only transcripts within the 500 399 
kb window of selected CpG sites were considered in the analysis (N=45,076 transcripts). To 400 
control for technical variation in the DNA methylation dataset, a principal component (PC) 401 
analysis of 600 negative control probes using 10,000 permutations was performed, and the 402 
residuals of a linear regression model using the first 5 PCs were estimated.  The effect of sex 403 
and Houseman cell proportions estimates were adjusted for in a second stage linear regression 404 
model. Two models were applied to control for technical and unwanted biological variation when 405 
estimating gene expression residuals. In the first one, sex and Houseman estimates were 406 
regressed out. In the second one, fourteen surrogate variables estimated using the sva R 407 
package were adjusted for in a second model including sex and Houseman estimates. A linear 408 
regression model of residuals of gene expression versus residuals of methylation was 409 
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performed. Multiple testing for both Rotterdam and INMA gene expression analyses was 410 
controlled using Benjamini-Hochberg FDR correction.   411 
 412 
Examination of polymorphic and cross-reactive probes 413 
The list of FDR significant CpGs was matched to the list of polymorphic and cross-414 
reactive CpGs provided by Chen et al.{Chen, 2013 #18} to identify potential problematic probes. 415 
We additionally performed the dip test{Hartigan, 1985 #161} for unimodality for each CpG to test 416 
for non-unimodal distributions in the MoBa1 cohort (N=1,068). Also using the MoBa1 cohort, we 417 
visually inspected density plots for each of the probes that matched to the list of polymorphic 418 
probes from Chen et al. to assess departures from unimodality, including from small numbers of 419 
outlier values. 420 
 421 
Results 422 
Study characteristics 423 
 A total of 13 cohorts participated in the meta-analysis of maternal smoking during 424 
pregnancy and 450K DNA methylation in newborns. Among these 6,685 newborns, 897 (13%) 425 
were exposed to sustained maternal smoking during pregnancy and 1,646 (25%) were exposed 426 
to any maternal smoking during pregnancy. We also included five cohorts of older children 427 
(N=3,187, average age = 6.8 years); 266 children (8%) were exposed to sustained smoking 428 
during pregnancy and 404 (13%) were exposed to any maternal smoking during pregnancy. The 429 
cohort-specific summary statistics for maternal smoking are presented in Table 1 and covariates 430 
in Supplemental Table S1. The majority of participants were of European ancestry 431 
(Supplemental Table S1).  432 
 433 
Meta-analysis  434 
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Our primary model evaluated the association between sustained maternal smoking 435 
during pregnancy and differential DNA methylation in newborns using normalized methylation 436 
betas as the outcome, adjusting for covariates (Figure 1). The cohort-specific lambdas and 437 
number of CpGs included in each model are listed in Supplemental Table S2. Among the 6,073 438 
CpGs with FDR significance (Supplemental Table S3), 568 also met the strict Bonferroni 439 
threshold for statistical significance (p value<1.08x10-7, correcting for 464,628 independent 440 
tests). Results were quite robust to cell type adjustment (Supplemental Table S3): all 568 441 
Bonferroni-significant CpGs from the primary model remained FDR-significant in the cell type 442 
adjusted model and 78% were Bonferroni significant in both models. The log10(p values) for the 443 
primary model and cell-type adjusted models were highly correlated (correlation coefficient = 444 
0.92 across all CpGs, 0.98 for the CpGs FDR-significant in the primary model, Supplemental 445 
Figure 1). Given the general similarity of the results before and after cell type adjustment and 446 
the fact that the available reference panel is from a small number (N=6) of adult men,{Reinius, 447 
2012 #56} we regard the covariate adjusted model as the primary model. The results for other 448 
models (the cell type adjusted model, the any smoking during pregnancy model, and the 449 
sustained smoking during pregnancy associated with older children methylation model) and the 450 
mean methylation values in newborns and older children are shown for all 6,073 CpGs in 451 
Supplemental Table S3. 452 
Among the 6,073 FDR-significant CpGs, smoking during pregnancy was associated 453 
approximately equally with increased methylation (52%) and decreased methylation (48%) 454 
(Figure 2). Out of the 3,932 CpGs that were also FDR-significant after cell type adjustment, 455 
there were 967 CpGs in or within 10 Mb of the 1,185 genes we identified in our systematic 456 
literature review (see methods, Supplemental Note and Supplemental Table S4) as previously 457 
reported to be differentially methylated in relation to smoking. This left 2,965 CpGs 458 
(corresponding to 2,017 annotated mapped or nearest genes) that had not previously been 459 
reported (Supplemental Table S5; genes highlighted in discussion shown in Table 2). For 460 
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comprehensive comparison with the previous literature, we also present our results for all CpGs 461 
that were either not FDR-significant after cell type adjustment and/or that annotated to genes 462 
already described in the literature as related to smoking and methylation (N=3,108 CpGs, 463 
Supplemental Table S6). Our top finding among the 6,073 FDR-significant CpGs was for AHRR 464 
(MIM: 606517) cg05575921 (p value = 1.64x10-193) which is the top most statistically significant 465 
CpG in many other studies evaluating either personal smoking or maternal smoking during 466 
pregnancy.  467 
We found our results to be robust to different analytic approaches. We present results 468 
from models using normalized betas as the outcome. When using raw betas as the outcome we 469 
observed little difference in the results (Spearman’s correlation coefficient = 0.96 for regression 470 
coefficients; 0.98 for log10(p values) for our significant findings). Furthermore, excluding the one 471 
cohort with newborns of non-European ancestry (NEST) from the sustained maternal smoking 472 
model provided similar results (Spearman’s correlation coefficient = 0.99 for regression 473 
coefficients; 0.89 for log10(p values). 474 
 475 
Examination of potentially polymorphic and cross-reactive probes  476 
A total of 742 of the 6,073 FDR significant CpGs overlapped with the list of 70,889 477 
potentially polymorphic probes provided by a supplemental table of Chen et al.{Chen, 2013 #18} 478 
Only 137 of the 6,073 FDR-significant CpGs overlapped with the list of 29,233 cross-reactive 479 
probes annotated by Chen et al. Many of the probes flagged by Chen are associated with very 480 
low frequency SNPs and thus are likely to have minimal impact on results in most datasets. In 481 
visual inspection of the density plots of all 742 such probes, we flagged 19 CpGs as having a 482 
possible deviation from unimodality (listed in Supplemental Table S7). However, results from the 483 
dip test{Hartigan, 1985 #161} applied to all 6,073 FDR significant CpGs identified only 4 CpGs 484 
as statistically significantly deviated from unimodality (FDR adjusted p<0.05; cg11459648, 485 
cg17847044, cg15028160, and cg25849281). 486 
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 487 
Persistence of DNA methylation related to maternal smoking during pregnancy in older children 488 
Because of the smaller sample size and smaller proportion of children exposed to 489 
maternal smoking in the older children models, we had less statistical power compared to the 490 
newborn models. When we compared the coefficients for newborns and older children for all 491 
6,073 CpGs, there were 4,403 (73%) with a consistent direction of effect and all 6,073 (100%) 492 
with nominal P values < 0.05 for the older children models which is higher than the 5% expected 493 
by chance alone (Kolmogorov p value < 2.2x10-16). Among these, 3,722 CpGs (61%) had a 494 
weaker effect size (attenuation) in the older children compared to newborns, but the attenuation 495 
overall was very small in magnitude and not significant (mean attenuation=-0.00039, 496 
SD=0.0059). Among the 148 CpGs that met FDR significance at look-up replication level in the 497 
older children (Supplemental Table S8), 100% were consistent in the direction of effect 498 
compared to newborns and there was attenuation for 32%, again small in magnitude and not 499 
significant (mean attenuation=-0.00008, SD=0.018).  500 
 501 
Enrichment analysis 502 
For our 6,073 FDR significant CpGs, we observed enrichment for localization to CpG 503 
island shores (35% versus 23% overall as compared to all CpGs on the array, p value=2.8x10-504 
100), enhancers (29% versus 22% overall, p value=5.7x10-45), and DNAse hypersensitivity sites 505 
(14% versus 12% overall, p value=2.8x10-7). Conversely, we found relative depletion in CpG 506 
islands (18% versus 31% overall, p value=9.1x10-116), FANTOM promoters (2.5% versus 6.7% 507 
overall, p value=2.1x10-49), and promoter associated regions (13% versus 19% overall, p 508 
value=2.3x10-33). There was no statistically significant enrichment or depletion of sites mapping 509 
to imprinted DMRs (0.082% versus 0.16% overall, p value=0.107).  510 
 511 
Pathway analysis 512 
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Our pathway analyses indicated that the FDR significant CpG sites corresponded to 513 
genes enriched for several categories of biological processes including anatomical 514 
development, phosphate-containing compound metabolism, nervous system development, and 515 
cell communication processes (Supplemental Figure 2). Based on DAVID, eight biological 516 
processes were enriched including GTPase signal transduction, neuronal differentiation, and 517 
protein kinase activity (Supplemental Figure 3). The top statistically significantly enriched 518 
diseases and biofunctions identified through Ingenuity software included tumor adhesion, 519 
neuron development, and connective tissue differentiation (Supplemental Figure 4). 520 
 521 
Functional network analysis 522 
 Functional network analysis revealed 447 significantly enriched GO terms after applying 523 
FDR correction (q-value <0.01 for this analysis, Supplemental Table S9). The majority of the 524 
enriched terms, and particularly the most statistically significant ones, pointed towards biological 525 
processes related to cell/tissue/organ development, proliferation, morphogenesis, differentiation, 526 
growth, and other biologically relevant processes. There were also several enriched processes 527 
related to embryonic morphogenesis/development. 528 
 529 
Methylation transcription analysis 530 
To assess transcriptional effects related to methylation differences, we investigated 531 
whether methylation status correlated with gene expression levels for our 2,965 CpGs 532 
associated with sustained maternal smoking in newborns that we identified through literature 533 
review as not having been previously reported. In the Rotterdam Study dataset of adults, out of 534 
the 2,636 (of the 2,965) CpGs that we were able to match to a gene transcript (+/- 250 kb), 254 535 
unique CpGs (343 total CpG-gene transcript associations) were significantly associated with 536 
expression of a nearby gene in whole blood from adults (FDR p value < 0.05, Supplemental 537 
Table S10). We observed strong associations for several CpGs annotated to the same gene 538 
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and corresponding gene expression levels, most strikingly for IL32 (MIM: 606001) with four 539 
CpGs associated with IL32 expression, and HOXB2 (MIM: 142967) with several CpGs related to 540 
HOXB2 expression (lowest p value 2.38 x 10-72, Supplemental Table S10). In the much smaller 541 
study of children at age four from INMA (N=107), 35 CpGs were associated with gene 542 
expression (FDR p value < 0.05). The following six genes had CpGs with methylation that was 543 
statistically significantly related to gene expression in both the Rotterdam Study adults and 544 
INMA children: ENOSF1 (MIM: 607427), HOXB2 (MIM: 142967, IL32 (MIM: 606001, NLRP2 545 
(MIM: 609364), PASK (MIM: 607505), and TDRD9. In both the adult and child datasets, for the 546 
majority of CpGs statistically significantly related with expression the direction was inverse 547 
(higher methylation, lower expression).  548 
 549 
DNA methylation related to any maternal smoking during pregnancy in newborns 550 
 In addition to the sustained smoking model we meta-analyzed the effect of any maternal 551 
smoking during pregnancy on newborn methylation. As expected, based on previous 552 
literature,12 we found that despite the much larger number of women with any smoking during 553 
pregnancy, there were fewer statistically significant findings for this less specific exposure 554 
(4,653 FDR-significant CpGs, Supplemental Table S3).  555 
 556 
Discussion 557 
We combined data across many studies in a large scale epigenome-wide meta-analysis 558 
to evaluate the association between maternal smoking during pregnancy and DNA methylation 559 
in offspring. We established the Pregnancy and Childhood Epigenetics (PACE) consortium to 560 
study this association and had 13 birth cohort studies from the US and Europe that measured 561 
CpG-specific DNA methylation across the epigenome in newborns with the same reproducible 562 
platform. Combining these studies resulted in the discovery of 6,073 statistically significant 563 
CpGs; 3,932 remained statistically significant after adjustment for cell type proportion. Our 564 
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results are remarkably robust to different modeling techniques. Findings were very similar when 565 
using either the raw methylation betas or the normalized betas as the outcome. This is despite 566 
the variety of data processing methods used across the cohorts for normalization and 567 
corrections for technical variables such as batch (described in the Supplemental Note). This 568 
consistency is reassuring given the range of published methods available for researchers to 569 
apply to 450K DNA methylation data for the quality control, normalization, and adjustment for 570 
technical variation. Furthermore, our main findings persisted after cell type adjustment 571 
(Supplemental Table S3, Supplemental Figure 1).  572 
As predicted, based on earlier evaluation of top findings for maternal smoking in the 573 
MoBa cohort,12 we had fewer statistically significant findings for any smoking during pregnancy 574 
than for sustained smoking during pregnancy (Supplemental Figure 5). Nonetheless, with the 575 
large sample size of this meta-analysis, we still observed many statistically significant CpGs 576 
after FDR correction in the any smoking models and the direction of effect and p values were 577 
similar to those from the sustained smoking models (Supplemental Table S3, Supplemental 578 
Figure 6). However, the stronger signal for sustained smoking suggests that this might be the 579 
more powerful variable for studying epigenetic effects and possible health outcomes from this 580 
exposure in offspring.  581 
Our observation of a large number of genome-wide significant CpGs related to maternal 582 
smoking is not surprising given reports of multiple genome-wide significant loci identified in 583 
single studies, all with smaller sample sizes.{Ivorra, 2015 #88;Joubert, 2012 #5;Markunas, 2014 584 
#7;Dogan, 2014 #92;Harlid, 2014 #93;Kupers, 2015 #99} Reassuringly, among our myriad 585 
findings, the top hit in all newborn models was AHRR cg05575921 (p value<1.64x10-193) which 586 
has been observed as differentially methylated in relation to smoking in many studies of adults 587 
and children. {Joubert, 2012 #5;Markunas, 2014 #7;Monick, 2012 #57;Shenker, 2013 588 
#58;Zeilinger, 2013 #59;Kupers, 2015 #99} 589 
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Our enrichment testing of the genome-wide results is in line with previous findings 590 
showing that island shores, enhancers, and DNase I hypersensitive sites are more dynamic 591 
(susceptible to methylation changes) than promoter regions{Ziller, 2013 #147}  and imprinted 592 
loci.{Ivanova, 2012 #148} These regions may be more resistant to changes in DNA methylation 593 
in response to in utero exposure.{Ivanova, 2012 #148} Thus, it is not surprising that 594 
associations between maternal smoking and newborn methylation may be more likely to be 595 
found in island shore and enhancer regions as opposed to promoters or CpG islands.  596 
To assess the underlying biology involved in the associated genomic regions, we applied 597 
pathway and functional analyses as well as tests of enrichment. These results implicated 598 
numerous neurological pathways, pathways involved in embryogenesis, and various 599 
developmental pathways. These observations may provide insight into the etiology of childhood 600 
health outcomes related to maternal smoking during pregnancy. 601 
We focus discussion on some specific genes among the associations that based on our 602 
systematic review had not been previously reported (2,965 CpGs annotating to 2,017 mapped 603 
or nearest genes). For 27 of these genes, mutations or SNPs have been implicated in 604 
susceptibility to orofacial clefts (as identified in the Snipper database review described in the 605 
Supplemental Note). This includes the following genes (each representing 1 FDR significant 606 
CpG unless otherwise specified): BHMT2 (MIM: 605932, 6 CpGs), GRHL3 (MIM: 608317), 607 
THADA (MIM: 611800), GAD67 (MIM: 605363), TP63 (MIM: 603273,2 CpGs), MSX1 (MIM: 608 
142983), WDR1 (MIM: 604734), SPP1 (MIM: 166490), BMP6 (MIM: 112266), TFAP2A (MIM: 609 
107580), COL11A2 (MIM: 120290,3 CpGs), PDGFRA (MIM: 173490), MN1 (MIM: 156100), 610 
MSX2 (MIM: 123101, 4 CpGs), PVT1 (MIM: 165140), ZIC2 (MIM: 603073), HOXA2 (MIM: 611 
604685, 10 CpGs), WNT3 (MIM: 165330), RUNX2 (MIM: 600211, 2 CpGs), TERT (MIM: 612 
187270), SPATA13 (MIM: 613324, 2 CpGs), VAX1 (MIM: 604294), TIMP2 (MIM: 188825), NOG 613 
(MIM: 602991), BEST3 (MIM: 607337), MYH9 (MIM: 160775), and BMP4 (MIM: 112262, 6 614 
CpGs) (results in Supplemental Table S5) . Although this does not imply that the smoking are 615 
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on the causal pathway, we note that the Surgeon General’s Report summarizes the evidence as 616 
sufficient to infer a causal relationship between maternal smoking during pregnancy and these 617 
birth defects.{US Department of Health and Human Services, 2014 #27} Many of these genes 618 
also have varied biological effects relevant to other aspects of development.  619 
Among this group of genes previously related to orofacial clefts, bone morphogenetic 620 
protein 4 (BMP4) is especially interesting. Maternal smoking might interact with SNPs in this 621 
gene in relation to oral clefts.{Chen, 2014 #97} We identified six CpGs in BMP4 at genome-wide 622 
significance in newborns; two remained statistically significant in the older children. In addition 623 
to orofacial clefts, SNPs in BMP4 are related to tooth development and eruption, as well as to 624 
colorectal cancer in GWAS.{Burdett,  #94} BMPs, including BMP4,45 also play an important role 625 
in lung development: reduced lung function among infants is an established consequence of 626 
maternal smoking during pregnancy.{US Department of Health and Human Services, 2014 #27} 627 
A plot showing greater detail on the CpGs in or near BMP4 is provided in Figure 3.  628 
We observed six CpGs significantly related to maternal smoking in betaine-629 
homocysteine methyltransferase (BHMT2; Supplemental Figure 7). Genetic variants in this gene 630 
have been associated with orofacial clefts in candidate gene studies{Mostowska, 2010 #130} 631 
and with selenium levels in GWAS.{Welter, 2014 #131;Hindorff,  #132} Of note, in experimental 632 
studies, selenium has been shown to protect against orofacial clefts induced by exposure to 633 
teratogens.{Ozolins, 1996 #133} In the Cancer Genome Atlas, methylation of BHMT2 in lung 634 
adenocarcinoma (lung cancer [MIM: 211980]) was strongly correlated (3rd rank genome-wide) 635 
with smoking history.{,  #134} 636 
The gene PRDM8 (PR domain containing 8, MIM: 616639) has the largest number of 637 
CpGs (18 of 61 based on Illumina annotation) significantly associated with maternal smoking 638 
during pregnancy. Maternal smoking during pregnancy was associated with decreased 639 
methylation throughout the gene. PRDM8 is one of several PRDMs belonging to the SET 640 
domain family of histone methyltransferases.{Fog, 2012 #72} PRDM genes either act as direct 641 
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histone methyltransferases or recruit a suite of histone-modifying enzymes to target 642 
promoters.{Hohenauer, 2012 #73} PRDM8 specifically methylates H3K9 of histones to repress 643 
transcriptional activity.{Eom, 2009 #71} PRDM8 expression is tightly regulated in a spatio-644 
temporal manner during neural development;{Komai, 2009 #76} it regulates morphological 645 
transition in neocortical development{Inoue, 2014 #74} and forms part of a repressor complex 646 
that directs, through regulation of Cadherin-11, neural circuit assembly.{Ross, 2012 #80} Thus 647 
PRDM8 appears to play an important role in neurologic development.  648 
DLGAP2 (discs, large (Drosophila) homolog-associated protein 2, MIM: 605438) is 649 
another gene with a large number of significant CpGs (14 of 192 tested CpGs) associated with 650 
maternal smoking in our study. DLGAP2 belongs to a gene family that encodes SAP90/PSD95-651 
associated proteins (SAPAPs), and SAPAP2 is known to be involved in the molecular 652 
organization of synapses and in neuronal cell signaling.{Takeuchi, 1997 #70} DLGAP2 was first 653 
identified in studies of progressive epilepsy with mental retardation (EPMR [MIM: 654 
610003]){Ranta, 2000 #69}, and has been associated with other central nervous system 655 
disorders such as schizophrenia (SCZD [MIM: 181500]){Li, 2014 #66} and autism spectrum 656 
disorders (ASD [MIM: 209850]).{Pinto, 2010 #68;Chien, 2013 #62} Differential methylation at 657 
this locus in a rat model appears to play a role in the development of post-traumatic stress 658 
disorder.{Chertkow-Deutsher, 2010 #61} 659 
The neuropilin-2 (NRP2, MIM: 602070) gene had 3 CpGs located in close proximity 660 
(among 48 tested) that were statistically significantly associated with maternal smoking during 661 
pregnancy. NRP2 is one of two transmembrane receptors for axonal guidance cues of the class 662 
3 semaphorin (SEMA) family and is expressed in sympathetic neural crest cells and their 663 
progeny.{Maden, 2012 #77} It may also be required in vivo for sorting migrating cortical and 664 
striatal interneurons to their correct destination.{Wu, 2007 #82} NRP2 also functions as a 665 
receptor for some forms of vascular endothelial growth factor, thereby playing a crucial role in 666 
angiogenesis and lymphangiogenesis.{Neufeld, 2002 #79} Polymorphisms in NRP2 have been 667 
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associated with several diseases including autism{Wu, 2007 #82} and multiple 668 
cancers.{Nasarre, 2013 #78;Jubb, 2012 #75;Yasuoka, 2011 #83;Samuel, 2011 #81;Yasuoka, 669 
2009 #84} 670 
Hypermethylation of ESR1 (estrogen receptor 1, MIM:133430; a key nuclear 671 
transcription factor) on chromosome 6q25.1 is well-studied in relation to presence and 672 
prognosis of various malignancies such as breast cancer and hepatocellular carcinoma{Gaudet, 673 
2009 #65;Dai, 2014 #63} as well as asthma.{Dijkstra, 2006 #152;Koppelman, 2011 #153} We 674 
found an inverse association between maternal smoking and methylation levels for seven out of 675 
the eight FDR significant ESR1 CpG sites. ESR1 hypomethylation has been reported in relation 676 
to induced microRNA expression (synthetic miR-29b oligonucleotides) in acute myeloid 677 
leukemia cells.{Garzon, 2009 #64;Garzon, 2009 #64;Garzon, 2009 #64;Garzon, 2009 #64}  678 
To evaluate possible functional gene expression effects of methylation at the CpGs that 679 
we found to be significantly related to maternal smoking, we analyzed data from two studies – 680 
one of adults and another of children at age four years. Although on first pass, one might expect 681 
a higher proportion of the CpGs related to maternal smoking to also be related to gene 682 
expression, there are several factors that decrease the likelihood of seeing significant 683 
associations. Most importantly, the sample size for discovery of the methylation association with 684 
smoking was much larger than the datasets available to correlate gene expression and 685 
methylation (about 10 fold smaller for the adult gene expression dataset and about 60 fold 686 
smaller for the childhood dataset). In addition, gene expression in blood may be more transient 687 
than methylation, decreasing the ability to find significant associations with a single gene 688 
expression measurement. Furthermore, constitutive gene expression is measured in this setting 689 
whereas many genes are inducible and methylation might contribute to this process. Lastly, 690 
some in utero-induced changes to methylation may have affected transcription during fetal 691 
development but not in postnatal life, and may have transcription-independent functional 692 
mechanisms. Nonetheless, we observed significant associations between methylation and gene 693 
26 
 
expression at six genes in both the adults and the children. The majority of CpGs significantly 694 
associated with expression were in the commonly expected direction of methylation related to 695 
gene silencing. Notably, CpGs in IL32 (Supplemental Figure 8), a proinflammatory cytokine 696 
involved in several diseases such as asthma{Meyer, 2012 #151} and cancer,{Joosten, 2013 697 
#100}, HOXB2, a transcription factor involved in development{Tumpel, 2002 #157} and several 698 
cancer forms{Boimel, 2011 #158} and PASK (PAS domain containing serine/threonine kinase), 699 
involved in glucose homeostasis,{DeMille, 2013 #129} were significantly associated with 700 
expression in both datasets.  701 
We analyzed the associations of CpGs with expression levels of genes within a region of 702 
250 kb up- or downstream of the CpG. Consensus on the optimal physical distance for these 703 
analyses is lacking. However, in a recent study, associations between CpGs and SNPs were 704 
the strongest when within close proximity (500 kb) of the CpG-site.{Zhang, 2014 #160} Despite 705 
the limitations with the expression datasets included in our study, we believe that the 706 
transcriptomics data provide functional support for our maternal smoking findings.  707 
In older children, all of the CpGs significantly associated with maternal smoking in 708 
newborns gave at least nominal levels of significance (p value < 0.05). This skew of the 709 
distribution of P values toward small values was much more than expected by chance 710 
(Kolmogorov p value < 2.2 x 10-16) demonstrating a very high level of replication and persistence 711 
of findings at birth into later childhood. This is consistent with and substantially extends a few 712 
previous reports.{Lee, 2015 #91;Richmond, 2015 #159} We had only very limited data with 713 
repeat measures in the same individuals so we could not meta-analyze change in methylation 714 
over time. 715 
This inaugural paper from the PACE consortium, represents a major effort to combine 716 
data from many studies in a large scale meta-analyses of epigenome-wide association studies 717 
of maternal smoking in relation to methylation in newborns. We report at least an order of 718 
magnitude more genes differentially methylated in response to maternal smoking than have 719 
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been identified in any previous study. This suggests that meta-analysis in epigenome-wide 720 
association studies produces similar success to that of genome-wide association SNP studies in 721 
the identification of biologically meaningful loci. The similarity in the results obtained using the 722 
raw betas compared to normalized betas generated using various methods indicates that 723 
cohort-specific processing methods do not interfere with the ability to perform meta-analysis.  724 
We identified nearly 3,000 CpGs corresponding to genes differentially methylated in 725 
offspring in relation to whether mothers smoked during pregnancy. Some of these genes have 726 
been implicated in genetic studies of orofacial clefts or asthma, both conditions related to 727 
maternal smoking in pregnancy and others in the pathogenesis of cancers that are associated 728 
with adult smoking, including lung, colorectal (CRC [MIM: 114500]) and liver (HCC [MIM: 729 
114550])2. We also find substantial persistence into later childhood of effects of maternal 730 
smoking identified in newborns. Our findings may implicate epigenetic mechanisms in the 731 
etiology of these exposure-disease relationships. This large scale study also provides 732 
confirmation of previously reported loci, many of which have not been previously replicated. 733 
Pathway analysis highlights the involvement of identified genes in various developmental 734 
pathways, and functional effects at the transcriptomics level were observed for many of the 735 
identified CpG sites. These findings may provide new insights into the mechanisms involved in 736 
the detrimental health outcomes that arise from this important in utero exposure.  737 
 738 
Supplemental Data Description 739 
Supplemental Data include 8 figures, 10 tables (6 in Excel format), and the supplemental note 740 
(supplemental materials and methods, acknowledgements, and funding information).    741 
 742 
Acknowledgements 743 
For all studies, information on funding and acknowledgements can be found in the 744 
Supplemental Data.  745 
28 
 
 746 
Web Resources 747 
The URLS for data presented herein are as follows: 748 
Snipper, http://csg.sph.umich.edu/boehnke/snipper 749 
The R Project for Statistical Computing, R v.3.0.2, http://www.r-project.org/ 750 
Infinium HumanMethylation450K v1.2 Product Files, 751 
http://support.illumina.com/downloads/infinium_humanmethylation450_product_files.html 752 
A Catalog of Published Genome-Wide Association Studies, http://www.genome.gov/gwastudies  753 
 754 
References 755 
 756 
Figure Legends 757 
 758 
Figure 1. Meta-analysis of the association between sustained maternal smoking during 759 
pregnancy and DNA methylation in newborn cord blood. A total of 6,073 CpGs were considered 760 
statistically significant using FDR correction (solid horizontal line); 568 Bonferroni significant 761 
(dashed horizontal line)). 762 
 763 
Figure 2. Volcano plot indicating the direction of effects for the meta-analysis of the association 764 
between sustained maternal smoking during pregnancy and DNA methylation in newborn cord 765 
blood. 766 
 767 
Figure 3. Meta-analysis results for the association between sustained maternal smoking during 768 
pregnancy and DNA methylation in newborn cord blood: CpGs in or near BMP4. Top pane: –769 
log10(P values) from the meta-analysis model, CpGs indicated by dots, color coded based on 770 
29 
 
pairwise correlation with neighboring CpGs. Middle panel: Annotation tracks for the plotted 771 
genomic region. Bottom panel: Pairwise correlation matrix across the displayed CpGs. 772 
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Tables 773 
Table 1. Smoking variable frequencies for the cohorts participating in meta-analyses: Newborns and older 774 
children 775 
Study Study population Na 
Exposed to sustained maternal 
smoking during pregnancy 
N (%) 
Exposed to any maternal 
smoking during pregnancy 
N (%) 
ALSPAC newborns 860 87 (10.1) 120 (14.0) 
CHAMACOS newborns 378 7 (1.9)b 24 (6.3) 
CHS newborns 85 NAb 22 (25.9) 
GECKO newborns 255 70 (27.5) 129 (50.6) 
Generation R newborns 883 129 (14.6) 220 (24.9) 
IOW newborns 90 9 (10.0)b 23 (25.6) 
MeDALL newborns 362 43 (11.9) 63 (17.5) 
MOBA1 newborns 1,063 156 (14.7) 312 (29.4) 
MOBA2 newborns 671 70 (10.4) 173 (25.8) 
MOBA3 newborns 252 28 (11.1) 73 (29.0) 
NEST newborns 413 69 (16.7) 136 (32.9) 
NFCS newborns 889 245 (27.6) 325 (36.6) 
VIVA newborns 485 14 (2.9)b 26 (5.4) 
ALSPAC older children 840 89 (10.6) 115 (13.7) 
BAMSE older children 347 26 (7.5) 43 (12.4) 
GALA II older children 569 40 (7.0) 76 (13.4) 
MeDALL older children 851 86 (10.2) 121 (14.3) 
SEED older children 584 25 (4.3) 49 (8.4) 
a N=number of participants with smoking data, 450K methylation, and covariates. Participants who quit smoking during 776 
pregnancy were not included in the sustained smoking models. 777 
b Cohorts where the sustained smoking category had N<15 or insufficient information to create the requested category, 778 
resulting in exclusion from the sustained smoking analysis models. All cohorts were included in the models evaluating the 779 
exposure any smoking during pregnancy. 780 
 781 
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Table 2. Meta-analysis results from newborns for selected loci not previously reported with genome-wide statistically significant differential methylation in 
newborn DNA in relation to sustained maternal smoking in pregnancy: Selection limited to genes prioritized for discussion.  
CHR Position CpG Mapped Gene 
Nearest Gene 
(10 Mb) 
Gene 
Group Coef SE P 
Direction of 
effect  
across 
cohorts Mean Beta 
1 24648203 cg06376426 GRHL3 GRHL3 TSS1500;Body -0.004 0.001 1.84E-04 -+------- 0.262 
2 43685377 cg20629315 THADA THADA Body 0.003 0.001 4.62E-04 --+++++++ 0.896 
2 206628553 cg22308949 NRP2 NRP2 Body -0.016 0.002 7.83E-12 --------- 0.413 
2 206628625 cg05348875 NRP2 NRP2 Body -0.026 0.004 1.13E-10 --------- 0.613 
2 206628692 cg14157435 NRP2 NRP2 Body -0.028 0.004 1.61E-10 --------- 0.413 
2 206692685 cg14400541 - NRP2 - -0.008 0.002 5.19E-05 +-------- 0.501 
3 189348936 cg05129081 TP63 TP63 TSS1500 0.012 0.002 1.21E-07 ++++++-++ 0.539 
3 189349021 cg06720722 TP63 TP63 TSS200 0.009 0.002 8.49E-06 ++++++-++ 0.798 
4 10117479 cg22821355 WDR1 WDR1 Body -0.007 0.002 1.50E-04 --------- 0.382 
4 81109888 cg01789499 PRDM8 PRDM8 5'UTR -0.009 0.002 1.86E-04 ------+-- 0.852 
4 81110205 cg09595050 PRDM8 PRDM8 5'UTR -0.018 0.004 1.71E-06 --------- 0.739 
4 81110459 cg14197071 PRDM8 PRDM8 5'UTR -0.021 0.005 5.33E-06 ------+-- 0.723 
4 81111177 cg27111250 PRDM8 PRDM8 5'UTR -0.020 0.005 1.61E-05 ------+-- 0.708 
4 81111393 cg27639662 PRDM8 PRDM8 5'UTR -0.016 0.004 3.33E-05 ------+-- 0.702 
4 81117647 cg05452645 PRDM8 PRDM8 TSS1500;5'UTR -0.022 0.004 8.95E-09 ------+-- 0.520 
4 81117665 cg00138041 PRDM8 PRDM8 TSS1500;5'UTR -0.021 0.004 1.39E-06 ------+-- 0.556 
4 81117853 cg06373870 PRDM8 PRDM8 TSS1500;5'UTR -0.017 0.003 1.24E-08 ------+-- 0.422 
4 81118188 cg03463411 PRDM8 PRDM8 TSS1500;5'UTR -0.014 0.003 1.09E-06 ------+-- 0.372 
4 81118343 cg04235768 PRDM8 PRDM8 TSS1500;5'UTR -0.014 0.002 1.35E-09 ------+-- 0.159 
4 81118588 cg26299084 PRDM8 PRDM8 5'UTR;TSS200 -0.012 0.003 1.98E-06 ------+-- 0.247 
4 81118794 cg06307913 PRDM8 PRDM8 5'UTR;1stExon -0.020 0.003 3.72E-09 ------+-- 0.424 
4 81119178 cg27242132 PRDM8 PRDM8 5'UTR -0.022 0.004 2.98E-09 ------+-- 0.240 
4 81119198 cg18073471 PRDM8 PRDM8 5'UTR -0.018 0.003 1.21E-08 ------+-- 0.178 
4 81119249 cg02458885 PRDM8 PRDM8 5'UTR -0.010 0.002 5.94E-06 ------+-- 0.189 
4 81119299 cg11388320 PRDM8 PRDM8 5'UTR -0.023 0.004 1.12E-08 --------- 0.324 
4 81119473 cg22902505 PRDM8 PRDM8 5'UTR -0.027 0.004 1.21E-10 ------+-- 0.433 
4 81122726 cg05522011 PRDM8 PRDM8 Body -0.015 0.004 2.00E-04 ------+-- 0.799 
5 78365647 cg01856645 DMGDH;BHMT2 BHMT2       TSS200;Body 0.008 0.002 3.35E-06 ++++++-++ 0.177 
5 78365687 cg06501366 BHMT2;DMGDH BHMT2       Body;TSS1500 0.018 0.003 1.11E-10 +++++++++ 0.408 
5 78365691 cg08328513 BHMT2;DMGDH BHMT2       Body;TSS1500 0.017 0.003 3.94E-09 ++++++-++ 0.265 
5 78365710 cg23911707 BHMT2;DMGDH BHMT2       Body;TSS1500 0.006 0.001 5.69E-06 +++++++++ 0.260 
5 78365801 cg03400060 BHMT2;DMGDH BHMT2       Body;TSS1500 0.012 0.002 2.96E-10 +++++++++ 0.392 
5 78366076 cg01902605 BHMT2;DMGDH BHMT2       Body;TSS1500 0.013 0.002 1.50E-09 +++++++++ 0.707 
6 7673306 cg25370658 - BMP6 - 0.004 0.001 2.63E-04 +++-+--++ 0.806 
6 7698374 cg17951878 - BMP6 - 0.013 0.003 1.15E-06 +++++++++ 0.286 
6 7731280 cg23623251 BMP6 BMP6 Body 0.006 0.002 3.25E-04 +++++++++ 0.783 
6 10405499 cg16199280 TFAP2A TFAP2A Body 0.006 0.002 3.26E-04 +-+++++++ 0.342 
6 55767865 cg16728651 - BMP5 - -0.010 0.002 1.05E-06 --------- 0.729 
6 152011415 cg08161546 ESR1 ESR1 TSS1500 0.008 0.002 3.50E-04 +-+++++++ 0.709 
6 152124815 cg08415493 ESR1 ESR1 5'UTR -0.003 0.001 1.74E-04 -+------- 0.706 
6 152126736 cg20893956 ESR1 ESR1 5'UTR;TSS200 -0.009 0.002 4.13E-05 --+---+-- 0.620 
6 152126785 cg07746998 ESR1 ESR1 5'UTR;TSS200 -0.006 0.002 1.18E-04 -+------- 0.594 
6 152126895 cg21157690 ESR1 ESR1 5'UTR;1stExon -0.008 0.002 5.70E-05 -++------ 0.747 
6 152126938 cg17264271 ESR1 ESR1 5'UTR;1stExon -0.009 0.002 1.26E-06 -++------ 0.627 
6 152130058 cg04063345 ESR1 ESR1 Body -0.013 0.004 1.22E-04 -++---+-- 0.507 
6 152130207 cg15626350 ESR1 ESR1 Body -0.018 0.004 1.42E-06 -+----+-- 0.444 
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CHR Position CpG Mapped Gene 
Nearest Gene 
(10 Mb) 
Gene 
Group Coef SE P 
Direction of 
effect  
across 
cohorts Mean Beta 
6 152130332 cg00601836 ESR1 ESR1 Body -0.014 0.003 1.19E-06 -++------ 0.676 
8 1403050 cg16442298 - DLGAP2 - -0.004 0.001 3.28E-04 --------- 0.716 
8 1404023 cg03551508 - DLGAP2 - -0.007 0.002 2.74E-05 --------- 0.746 
8 1427491 cg00827210 - DLGAP2 - -0.007 0.001 4.83E-07 ------+-- 0.882 
8 1442292 cg13063207 - DLGAP2 - -0.006 0.001 1.85E-05 --------- 0.847 
8 1458508 cg24526596 DLGAP2 DLGAP2 5'UTR -0.005 0.001 2.52E-04 ------+-- 0.590 
8 1462903 cg25955692 DLGAP2 DLGAP2 5'UTR -0.005 0.001 1.67E-05 ++------- 0.874 
8 1468625 cg00598912 DLGAP2 DLGAP2 5'UTR -0.003 0.001 1.39E-04 --------- 0.831 
8 1494546 cg23424125 DLGAP2 DLGAP2 5'UTR -0.010 0.003 3.23E-04 ------+-- 0.850 
8 1501226 cg03185622 DLGAP2 DLGAP2 Body -0.005 0.001 5.33E-07 +----+--- 0.825 
8 1526540 cg15833940 DLGAP2 DLGAP2 Body -0.013 0.003 6.70E-06 --------- 0.659 
8 1534376 cg02840179 DLGAP2 DLGAP2 Body -0.004 0.001 1.05E-04 --------- 0.816 
8 1615080 cg02709139 DLGAP2 DLGAP2 Body -0.007 0.002 1.32E-05 ------+-- 0.870 
8 1616381 cg04687241 DLGAP2 DLGAP2 Body -0.008 0.002 6.92E-06 -+------- 0.666 
8 1618448 cg06040034 DLGAP2 DLGAP2 Body -0.013 0.003 2.42E-06 --------- 0.619 
8 1649758 cg02083412 DLGAP2 DLGAP2 3'UTR -0.004 0.001 3.15E-05 --------+ 0.129 
8 1649868 cg22763586 DLGAP2 DLGAP2 3'UTR -0.013 0.003 5.83E-07 ------+-- 0.450 
8 1650172 cg27351978 DLGAP2 DLGAP2 3'UTR -0.015 0.004 8.69E-05 ------+-- 0.566 
8 1650309 cg02690013 DLGAP2 DLGAP2 3'UTR -0.013 0.003 9.92E-06 ------+-- 0.599 
14 54412780 cg23104439 - BMP4 - 0.005 0.001 2.08E-04 ++++++++- 0.741 
14 54418728 cg05928290 BMP4 BMP4 Body 0.024 0.003 1.48E-19 +++++++++ 0.759 
14 54418804 cg05923197 BMP4 BMP4 Body 0.029 0.003 1.08E-18 +++++++++ 0.699 
14 54418851 cg09367901 BMP4 BMP4 Body 0.019 0.002 3.98E-17 +++++++++ 0.827 
14 54419614 cg08046044 BMP4 BMP4 5'UTR 0.005 0.001 2.70E-09 +++-+++++ 0.077 
14 54424149 cg24526899 BMP4 BMP4 TSS1500 0.007 0.002 5.14E-04 ++++++++- 0.441 
17 76930245 cg04999637 - TIMP2 - 0.005 0.001 6.91E-05 +++++++++ 0.583 
a Meta-analysis results of the association between sustained maternal smoking during pregnancy and DNA methylation in newborns, adjusted for covariates, using normalized methylation betas as the 
outcome. Selected not previously reported loci genome wide significant after FDR correction. Results sorted by the chromosome and position of the CpG sites listed. Column headers: CHR: chromosome; 
Mapped Gene: UCSC annotated gene; Nearest Gene: Nearest gene (within 10 Mb) symbol using Snipper software; Gene Group: UCSC gene region feature category; Coef: regression coefficient; SE: 
standard error; P: p value; Direction: Direction of effect across cohorts included in the statistical model: maternal smoking during pregnancy associated with increased (+) or decreased (-) methylation, or 
missing result (?), in alphabetical order of cohorts; Mean beta: Average of the mean methylation beta values across the newborn cohorts.  For complete listing of CpGs differentially methylated in relation 
to sustained maternal smoking during pregnancy and for results from meta-analysis models unadjusted for covariates and adjusted for covariates and cell type see Supplementary Table 3. 
 
 
 
